Ligand Pharmaceuticals Incorporated (LGND) Q4 2018 Earnings Results

Ligand Pharmaceuticals Beats on EPS, Stock Down 0.95%

Ligand Pharmaceuticals reported a strong EPS, beating expectations by a significant margin. However, the stock fell by 0.95% in reaction, indicating that investors may have been looking for more comprehensive revenue details or future guidance. The lack of revenue figures and guidance could have contributed to the stock's decline despite the positive EPS surprise.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$1.70	N/A	+29.01%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Cautiously Optimistic

Overall, management conveyed a sense of cautious optimism regarding the company's financial health. They emphasized the positive EPS surprise as a sign of effective cost management.

Management highlighted the strong performance in EPS despite not providing revenue figures.

They expressed confidence in their strategic direction moving forward.

Ligand Pharmaceuticals Beats on EPS, Stock Down 0.95%

Key numbers

Management commentary

Ligand Pharmaceuticals Incorporated

More earnings this week

Ligand Pharmaceuticals Beats on EPS, Stock Down 0.95%

Key numbers

Management commentary